| Recruiting | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555 | Beijing Biotech | Phase 1 / Phase 2 |
| Recruiting | Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Ch NCT07414758 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 3 |
| Recruiting | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma NCT07356245 | Jonathan Brammer | Phase 2 |
| Recruiting | A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripher NCT07389616 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2 / Phase 3 |
| Not Yet Recruiting | A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. NCT07180771 | Boryung Pharmaceutical Co., Ltd | Phase 2 |
| Recruiting | T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR NCT07353840 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicent NCT07253129 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | Amping up With PemJAK NCT07283822 | Seda S. Tolu | Phase 2 |
| Recruiting | Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study NCT07270861 | Fudan University | — |
| Recruiting | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690 | Baylor College of Medicine | Phase 1 |
| Not Yet Recruiting | Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma NCT07209163 | Ruijin Hospital | Phase 1 / Phase 2 |
| Recruiting | T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR NCT07470996 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Exp NCT07055477 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or R NCT07093710 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lym NCT06385522 | Boston Immune Technologies and Therapeutics | Phase 1 |
| Not Yet Recruiting | Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lympho NCT07032532 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers NCT06870487 | Pfizer | Phase 1 |
| Recruiting | A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies NCT06914037 | Tianjin Medical University Cancer Institute and Hospital | Phase 1 |
| Recruiting | A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Managem NCT06630091 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma NCT06757387 | Peking University Cancer Hospital & Institute | Phase 1 / Phase 2 |
| Withdrawn | Tazemetostat Plus CHOP in 1L T-cell Lymphoma NCT06692452 | Eric Jacobsen, MD | Phase 2 |
| Not Yet Recruiting | Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) NCT06712173 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients NCT07072221 | The First Affiliated Hospital of Soochow University | N/A |
| Not Yet Recruiting | A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell L NCT06548347 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 2 / Phase 3 |
| Recruiting | Golidocitinib Plus CHOP in Newly Diagnosed PTCL NCT06739265 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Recruiting | RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. NCT06468267 | Xianmin Song, MD | Phase 2 |
| Recruiting | Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL NCT06509945 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | N/A |
| Active Not Recruiting | A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL). NCT06550336 | The First Hospital of Jilin University | Phase 2 |
| Recruiting | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma NCT06433362 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Linperlisib Combined With Chidamide in Patients With PTCL NCT06421948 | Yanyan Liu | Phase 1 / Phase 2 |
| Recruiting | A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) NCT07234162 | Dizal Pharmaceuticals | Phase 3 |
| Completed | Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy NCT06422247 | Bristol-Myers Squibb | — |
| Recruiting | Circulating Tumor DNA in Peripheral T-cell Lymphomas NCT06362148 | University of Aarhus | — |
| Recruiting | GVM±R in Patients With Relapsed or Refractory Aggressive NHL. NCT06244368 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma NCT06508463 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas NCT06089941 | Centre Henri Becquerel | — |
| Recruiting | A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma NCT06173999 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma NCT04234048 | SciTech Development, Inc. | Phase 1 |
| Recruiting | Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma NCT06151106 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801 | Children's Hospital Medical Center, Cincinnati | — |
| Not Yet Recruiting | (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) NCT05923502 | Ruijin Hospital | — |
| Terminated | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL NCT05883449 | Affimed GmbH | Phase 2 |
| Active Not Recruiting | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T- NCT05377827 | Washington University School of Medicine | Phase 1 |
| Recruiting | To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL NCT06072131 | Acrotech Biopharma Inc. | Phase 3 |
| Unknown | Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center NCT06083701 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Unknown | Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positi NCT05979792 | Zhao Weili | EARLY_Phase 1 |
| Recruiting | Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma NCT05949944 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Recruiting | Go-CHOP as the Frontline Therapy for PTCL NCT05963347 | Henan Cancer Hospital | Phase 2 |
| Recruiting | Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST) NCT05934864 | Ruijin Hospital | — |
| Not Yet Recruiting | Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma NCT05900089 | Henan Cancer Hospital | Phase 1 |
| Active Not Recruiting | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers NCT05749549 | Shanghai Blueray Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treat NCT05958719 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Withdrawn | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies NCT03999658 | Sorrento Therapeutics, Inc. | Phase 2 |
| Recruiting | Genotype-guided Treatment in Newly Diagnosed PTCL NCT05675813 | Ruijin Hospital | Phase 1 / Phase 2 |
| Withdrawn | Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Pa NCT05239910 | Rhizen Pharmaceuticals SA | Phase 2 |
| Unknown | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes NCT05559008 | Ruijin Hospital | Phase 1 / Phase 2 |
| Unknown | A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Aza NCT05495100 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | Transplantation After Complete Response In Patients With T-cell Lymphoma NCT05444712 | Hospices Civils de Lyon | N/A |
| Unknown | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma NCT05458180 | Tianjin Medical University Cancer Institute and Hospital | Phase 1 |
| Completed | AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) NCT06511895 | Dizal Pharmaceuticals | Phase 2 |
| Completed | Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies NCT05290155 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 1 |
| Unknown | Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL NCT05441761 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express NCT05321147 | Innate Pharma | Phase 1 |
| Completed | AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) NCT06511869 | Dizal Pharmaceuticals | Phase 2 |
| Terminated | PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell NCT05083208 | Henan Cancer Hospital | Phase 1 |
| Completed | A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignan NCT05269940 | Nanjing Zenshine Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Study of Lacutamab in Peripheral T-cell Lymphoma NCT04984837 | The Lymphoma Academic Research Organisation | Phase 2 |
| Active Not Recruiting | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma NCT04526834 | Tessa Therapeutics | Phase 1 |
| Unknown | Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL NCT04052659 | Peking University | Phase 2 |
| Active Not Recruiting | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refrac NCT04668690 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 |
| Recruiting | Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma NCT04922567 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Suspended | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies NCT04828174 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 1 |
| Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients NCT04858568 | University Hospital Southampton NHS Foundation Trust | — |
| Withdrawn | PLM60 for Peripheral T Cell Lymphoma (PTCL) NCT03553914 | Conjupro Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment o NCT04548700 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Completed | Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Mali NCT04447027 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL） NCT04615468 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Unknown | The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell L NCT04489264 | Peking University | — |
| Recruiting | Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma NCT04512534 | Fudan University | Phase 2 |
| Completed | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression NCT04569032 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Unknown | The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL). NCT04457830 | Shandong New Time Pharmaceutical Co., LTD | Phase 2 |
| Unknown | Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cel NCT04880746 | Ruijin Hospital | Phase 3 |
| Completed | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Trea NCT04312841 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Recruiting | Evaluate the Safety and Clinical Activity of HH2853 NCT04390737 | Haihe Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Mo NCT04425070 | Antengene Corporation | Phase 1 / Phase 2 |
| Unknown | A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma NCT04470141 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 2 |
| Unknown | Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma NCT04480099 | Ruijin Hospital | Phase 2 |
| Unknown | Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemothera NCT04480125 | Ruijin Hospital | Phase 2 |
| Terminated | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer NCT04254107 | Seagen Inc. | Phase 1 |
| Terminated | A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma NCT04444141 | Akeso | Phase 1 / Phase 2 |
| Completed | BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) NCT04018248 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positi NCT04213209 | Takeda | — |
| Recruiting | A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma NCT04045470 | Dana-Farber Cancer Institute | N/A |
| Completed | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungo NCT04101331 | Affimed GmbH | Phase 2 |
| Terminated | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing P NCT03947255 | Seagen Inc. | Phase 2 |
| Unknown | γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) NCT04028440 | Institute of Hematology & Blood Diseases Hospital, China | EARLY_Phase 1 |
| Recruiting | CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma NCT04083495 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Unknown | PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma NCT04040491 | Mingzhi Zhang | Phase 4 |
| Unknown | A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma NCT04061772 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies NCT04068597 | CellCentric Ltd. | Phase 1 / Phase 2 |
| Unknown | Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies NCT04008394 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Unknown | Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma NCT03952572 | Peking University | Phase 3 |
| Completed | Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed NCT03927105 | University of Michigan Rogel Cancer Center | Phase 2 |
| Recruiting | Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma NCT03719105 | New York Medical College | EARLY_Phase 1 |
| Completed | Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas NCT03586999 | University of Colorado, Denver | Phase 1 / Phase 2 |
| Recruiting | Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. NCT03964480 | Associazione Angela Serra per la ricerca sul cancro | — |
| Unknown | Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) NCT03502629 | Genor Biopharma Co., Ltd. | Phase 2 |
| Unknown | Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma NCT03553537 | Southwest Hospital, China | Phase 3 |
| Completed | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms NCT03493451 | BeiGene | Phase 2 |
| Completed | A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) NCT03372057 | SecuraBio | Phase 2 |
| Unknown | Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects NCT03629873 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Completed | Romidepsin Maintenance After Allogeneic Stem Cell Transplantation NCT02512497 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Completed | Minimal Residual Disease in Peripheral T-cell Lymphoma NCT03297697 | Washington University School of Medicine | — |
| Unknown | Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Pred NCT03268889 | The First Affiliated Hospital of Soochow University | N/A |
| Unknown | Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) NCT03321890 | Sun Yat-sen University | Phase 2 |
| Unknown | Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexametha NCT03071822 | The University of Hong Kong | Phase 4 |
| Unknown | Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphom NCT03023358 | Nanfang Hospital, Southern Medical University | Phase 3 |
| Unknown | Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients NCT03079947 | Peking Union Medical College Hospital | — |
| Unknown | Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas NCT02495415 | CerRx, Inc. | Phase 2 |
| Unknown | The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas NCT03000738 | Peking Union Medical College Hospital | — |
| Unknown | Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma NCT02856997 | Yuankai Shi | Phase 2 |
| Unknown | A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy NCT03150602 | Taiwan Mundipharma Pharmaceuticals Ltd. | Phase 4 |
| Completed | Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients NCT02809573 | Chipscreen Biosciences, Ltd. | Phase 1 |
| Completed | Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphom NCT03212937 | National Cancer Centre, Singapore | Phase 1 |
| Completed | Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphom NCT02676778 | Eisai Co., Ltd. | Phase 2 |
| Completed | A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) NCT02653976 | Solasia Pharma K.K. | Phase 2 |
| Unknown | Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma NCT02944812 | Guangdong Provincial People's Hospital | Phase 2 |
| Unknown | Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma NCT02753543 | Ruijin Hospital | Phase 2 |
| Unknown | Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PT NCT02445404 | Samsung Medical Center | Phase 2 |
| Completed | Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma NCT03141203 | University of Birmingham | Phase 1 / Phase 2 |
| Completed | A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leuk NCT01614197 | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 |
| Unknown | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma NCT02232516 | Northwestern University | Phase 2 |
| Terminated | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors NCT02440685 | Asana BioSciences | Phase 1 / Phase 2 |
| Completed | Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL NCT02362997 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgki NCT01769911 | Fred Hutchinson Cancer Center | N/A |
| Completed | Carfilzomib Plus Belinostat in Relapsed/Refractory NHL NCT02142530 | Massachusetts General Hospital | Phase 1 |
| Completed | ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas NCT02264613 | Aileron Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lym NCT02168140 | Wake Forest University Health Sciences | Phase 1 |
| Terminated | Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 NCT01841021 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Completed | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Ce NCT01959477 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell L NCT02013362 | Mundipharma K.K. | Phase 1 / Phase 2 |
| Withdrawn | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Maligna NCT01652014 | University of Medicine and Dentistry of New Jersey | Phase 2 |
| Completed | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma NCT01748721 | Morphotek | Phase 1 |
| Enrolling By Invitation | BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphom NCT07258680 | N.N. Petrov National Medical Research Center of Oncology | Phase 3 |
| Completed | Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B NCT01846390 | Canadian Cancer Trials Group | Phase 1 |
| Completed | Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) NCT01839097 | Acrotech Biopharma Inc. | Phase 1 |
| Completed | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01839916 | University of Chicago | Phase 2 |
| Terminated | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas NCT01805037 | Northwestern University | Phase 1 / Phase 2 |
| Terminated | Ipilimumab and Local Radiation for Selected Solid Tumors NCT01769222 | Stanford University | Phase 1 |
| Completed | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies NCT01767766 | TG Therapeutics, Inc. | Phase 1 |
| Completed | Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients NCT01822886 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Completed | Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma NCT01796002 | The Lymphoma Academic Research Organisation | Phase 3 |
| Completed | A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL NCT01716806 | Seagen Inc. | Phase 2 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Terminated | Phase 1b Safety and Efficacy Study of TRU-016 NCT01644253 | Aptevo Therapeutics | Phase 1 |
| Completed | A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea NCT01689220 | Solasia Pharma K.K. | Phase 1 |
| Terminated | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic L NCT01419795 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) NCT01611142 | Kyowa Kirin Co., Ltd. | Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies NCT01523223 | Robert Lowsky | Phase 1 |
| Terminated | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgki NCT01408043 | Case Comprehensive Cancer Center | N/A |
| Completed | A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) NCT01435863 | Solasia Pharma K.K. | Phase 1 |
| Completed | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Trans NCT01427881 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Treatment of Peripheral T-cell Lymphoma NCT01664975 | Mingzhi Zhang | Phase 4 |
| Terminated | Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patien NCT01420679 | Spectrum Pharmaceuticals, Inc | Phase 3 |
| Completed | Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma NCT01336933 | University of Nebraska | Phase 2 |
| Completed | E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma NCT01401530 | Eisai Co., Ltd. | Phase 1 |
| Completed | Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma NCT01336920 | University of Nebraska | Phase 1 |
| Completed | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignanci NCT01658319 | Case Comprehensive Cancer Center | Phase 1 |
| Withdrawn | A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Per NCT01355783 | Eisai Inc. | Phase 3 |
| Completed | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT01261247 | Mayo Clinic | Phase 2 |
| Completed | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma NCT01075321 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymph NCT01280526 | The Lymphoma Academic Research Organisation | Phase 1 / Phase 2 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma NCT01258998 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilizati NCT01110135 | University of Washington | Phase 2 |
| Completed | Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 NCT01226472 | Kyowa Kirin Co., Ltd. | Phase 2 |
| Completed | A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients Wit NCT01169298 | Celgene | Phase 1 |
| Completed | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lympho NCT01129193 | Amir Mortazavi | Phase 1 |
| Completed | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma NCT01129180 | Pierluigi Porcu | Phase 1 |
| Terminated | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin L NCT01116154 | City of Hope Medical Center | Phase 1 |
| Completed | Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry NCT01110733 | Acrotech Biopharma Inc. | — |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT00891072 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating NCT00933985 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma NCT00888927 | Kyowa Kirin Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma NCT00865969 | Spectrum Pharmaceuticals, Inc | Phase 2 |
| Terminated | Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patien NCT01036399 | University of Bologna | Phase 2 |
| Terminated | Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Onta NCT00632827 | University of California, San Francisco | Phase 2 |
| Completed | T-Cell Project: Epidemiologic Component NCT00705809 | National Cancer Institute (NCI) | — |
| Completed | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma NCT00644189 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Completed | A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma NCT00426764 | Celgene | Phase 2 |
| Completed | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, NCT00458731 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Mal NCT00481871 | Acrotech Biopharma Inc. | Phase 1 / Phase 2 |
| Completed | A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies NCT00406809 | AbbVie (prior sponsor, Abbott) | Phase 1 / Phase 2 |
| Terminated | The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL NCT00441025 | Mahidol University | Phase 2 |
| Completed | Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cel NCT00364923 | Acrotech Biopharma Inc. | Phase 2 |
| Completed | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in T NCT00536601 | Roswell Park Cancer Institute | N/A |
| Completed | Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma NCT00136565 | Lymphoma Study Association | Phase 2 |
| Terminated | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell L NCT00274651 | Valerio Therapeutics | Phase 2 |
| Completed | A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cel NCT00337987 | Yale University | Phase 2 |
| Completed | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma NCT00131937 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Per NCT00930605 | King Chulalongkorn Memorial Hospital | Phase 2 |
| Terminated | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or NCT00101205 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Ce NCT01470066 | Chonnam National University Hospital | — |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Trea NCT00072514 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma NCT01806337 | University of Göttingen | Phase 2 |
| Completed | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer NCT00049504 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT NCT00791947 | University of Aarhus | Phase 2 |
| Completed | Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma NCT00007345 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant NCT00571662 | University of Nebraska | Phase 2 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |
| Terminated | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymph NCT01678443 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte I NCT00003196 | Fred Hutchinson Cancer Center | N/A |
| Completed | Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma NCT00970385 | University Hospital, Grenoble | Phase 3 |
| Completed | A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies NCT00038025 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371 | Case Comprehensive Cancer Center | Phase 2 |
| Available | Karyopharm Expanded Access Program for Selinexor NCT07215832 | Karyopharm Therapeutics Inc | — |